Ascendis Pharma A/S Ordinary Share (ASND)
ASND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/0001193125-26-046590-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ASND on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | 2015 |
| SEC CIK | 0001612042 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Denmark |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $795.9M |
| Net income | -$252.0M |
| Operating income | -$150.6M |
| Net margin | -31.7% |
| Operating margin | -18.9% |
| Revenue growth | +98.0% |
| Cash | $680.8M |
| Total assets | $1.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 22.5× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-11 |
| Cash and burn | 616.0M EUR cash; operating cash flow 13.5M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 61,977,408 (2025-12-31); 60,689,487 a year earlier; 57,152,295 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $777K, sold $5.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 720.1M EUR | -228.0M EUR | 53.9M EUR | 616.0M EUR | 720.3M EUR | 720.1M EUR | 20-F 2026-02-11 |
| FY 2024 2024-12-31 | 363.6M EUR | -378.1M EUR | -306.2M EUR | 559.5M EUR | 763.6M EUR | 363.6M EUR | 20-F 2026-02-11 |
| FY 2023 2023-12-31 | 266.7M EUR | -481.4M EUR | -467.4M EUR | 392.2M EUR | 545.5M EUR | 266.7M EUR | 20-F 2026-02-11 |
| FY 2022 2022-12-31 | 51.2M EUR | -583.2M EUR | -495.7M EUR | 444.8M EUR | 399.2M EUR | 51.2M EUR | 20-F 2025-02-12 |
| FY 2021 2021-12-31 | 7.8M EUR | -383.6M EUR | -417.6M EUR | 446.3M EUR | 105.0M EUR | 7.8M EUR | 20-F 2024-02-07 |
| FY 2020 2020-12-31 | 7.0M EUR | -419.0M EUR | -271.5M EUR | 584.5M EUR | No debt tags | 7.0M EUR | 20-F 2023-02-16 |
| FY 2019 2019-12-31 | 13.4M EUR | -218.0M EUR | -175.9M EUR | 598.1M EUR | No debt tags | 13.4M EUR | 20-F 2022-03-02 |
| FY 2018 2018-12-31 | 10.6M EUR | -130.1M EUR | -138.8M EUR | 277.9M EUR | No debt tags | 10.6M EUR | 20-F 2021-03-10 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-09-20 |
| Latest annual report | 20-F | 2026-02-11 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 801 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.2% |
| 1 month | +23.4% |
| 3 months | +11.8% |
| Year to date | +29.1% |
| 1 year | +33.4% |
| From 52-week high | -0.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| ELAN | Elanco Animal Health Incorporated | $26.41 | -1.38% | $13.2B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| RDY | Dr. Reddy's Laboratories Ltd | $14.70 | -0.27% | $12.3B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier